CBL-514

But if we developed a drug that was great for creating autophagy, we would digest and destroy normal cells as well as fat cells.

But what they've done in a new breakthrough, the new drug is called CBL-514.

They haven't named it.

It was highlighted in an annual meeting of the European Association of the Study of Diabetes in Milan.

So far, this is in what's called the preclinical stage.

Animal studies are promising.

When they combine CBL-514 with trisepatide, which is Majaro, it produced greater weight loss than treatment with just Majaro alone.

And then, this is in rats.

All right.

So anyone try CBL-514 yet?

Not yet, but it's on my radar.

So interesting compound.

All right, let's get going.

I wanna talk to you about CBL, CBL-514, because it crossed on my radar this week, um, and made pretty big headline.

But it is, of course, um, experimental, and it's an injectable called CBL-514, and it's been developed for two things women in midlife ask me about constantly, stubborn fat, that fat that won't shift, and cellulite.

Now, before anybody gets excited and starts, you know, researching where they can buy it, you can't.

Um, it is not approved anywhere.

But I think it's worth understanding because it tells us where this whole field is heading, and it's a great case study in how to read a breakthrough headline without getting swept away.

I got a little bit swept away 'cause this stuff fascinates me.

So what is it? CBL-514 comes from a Taiwanese company called Caloway Biopharmaceuticals.

That's that visceral fat.

This drug called CBL-514 specifically triggers fat cells to enter death programs called apoptosis.

So it is slightly related to this week's episode.

People who got injections of the experimental drugs in their lower abdomen lost visceral fat.

The team already knew the expensive drug could reduce the subcutaneous fat, that's the pinchable fat that sits on the skin in the abdomen, That surface fat doesn't carry the same health risks as the visceral fat does.

In this new study, researchers examined MRIs from a subset of participants in two small clinical trials to track visceral fat levels.

The study participants who ranged from healthy weights to overweight got injected with the CBL-514 or placebo every three weeks for up to 12 weeks the two groups started with about the same amount of visceral fat so that's 642 milliliters on average in the cbl group and 677 milliliters in the placebo group four weeks after treatment those who got the experimental drug had dropped almost 71 milliliters of visceral fat which is a 12 decrease while the placebo group gained 31 millisies which they gain 6% or increase of the dangerous fat around their abdomens I wonder if that's to do with the psychology of thinking that you're getting a drug that is causing you to lose weight do you think ah I'm getting that maybe I can eat more and it's okay I wonder if that's got something to do something weird along those lines that's got something to do with it The measurements taken at the 8 to 12 weeks after the treatment showed that the gap had even winded.

So those who got the expanded muscle drug lost almost 63 milliliters, which is a fair amount of visceral fat on average, while the placebo group gained more than 78 milliliters of visceral fat over the starting points of the last Yeah, that's